The COVID-19 pandemic will forever change drug and vaccine manufacturing, says an expert, who argues an Industry 4.0 approach will be vital.
Efforts to develop a vaccine against the SARS-CoV-2 virus are accelerating. Some of the candidates are traditional-type vaccines such as inactivated and attenuated products. But the majority are more modern DNA, RNA, and protein sub-unit vaccines.
The large number of innovative candidates in the list reflects the urgency of the situation, notes Parviz A. Shamlou, PhD, executive director and head of the Jefferson Institute for Bioprocessing (JIB) at Thomas Jefferson University.
